Literature DB >> 12665648

The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia.

Simon J Raphael1.   

Abstract

This review article primarily discusses immunohistochemical markers used to aid the diagnosis of thyroid neoplasia. The review concentrates on high molecular weight cytokeratins, cytokertain 19, HBME-1, and galectin-3. Diagnostic uses of proliferation markers such as p27(kip1) and Ki-67 are discussed along with the oncogene ret in relation to papillary carcinomas and PAX8-peroxisome proliferator-activated receptor gamma1 in relation to follicular carcinoma. The diagnostic use of retinoblastoma tumor suppressor gene product is also discussed. The sensitivities and specificities as well as the pitfalls of these techniques are reviewed. On the basis of the literature, the most highly recommended of these markers to aid in diagnosis are HBME-1 and galectin-3.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12665648     DOI: 10.1385/ep:13:4:301

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  29 in total

1.  Cyclin-dependent kinase inhibitor p27(Kip1) expression in thyroid cells obtained by fine-needle aspiration biopsy: a preliminary report.

Authors:  G Troncone; F Fulciniti; P Zeppa; A Vetrani; A Caleo; L Palombini
Journal:  Diagn Cytopathol       Date:  2000-08       Impact factor: 1.582

Review 2.  Interpretation and quantification of immunostains.

Authors:  T Seidal; A J Balaton; H Battifora
Journal:  Am J Surg Pathol       Date:  2001-09       Impact factor: 6.394

3.  Retinoblastoma expression in thyroid neoplasms.

Authors:  F Anwar; M J Emond; R A Schmidt; H C Hwang; M P Bronner
Journal:  Mod Pathol       Date:  2000-05       Impact factor: 7.842

4.  Immunohistochemical diagnosis of papillary thyroid carcinoma.

Authors:  C C Cheung; S Ezzat; J L Freeman; I B Rosen; S L Asa
Journal:  Mod Pathol       Date:  2001-04       Impact factor: 7.842

5.  Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours.

Authors:  M Miettinen; P Kärkkäinen
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

6.  Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.

Authors:  P L Fernández; M J Merino; M Gómez; E Campo; T Medina; V Castronovo; X Sanjuán; A Cardesa; F T Liu; M E Sobel
Journal:  J Pathol       Date:  1997-01       Impact factor: 7.996

7.  The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis.

Authors:  S Wang; J Wuu; L Savas; N Patwardhan; A Khan
Journal:  Hum Pathol       Date:  1998-11       Impact factor: 3.466

8.  Proliferation Markers and Their Uses in the Study of Endocrine Tumors.

Authors:  Giuseppe Pelosi; Giuseppe Zamboni
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

9.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.

Authors:  X C Xu; A K el-Naggar; R Lotan
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

10.  High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.

Authors:  S J Raphael; G McKeown-Eyssen; S L Asa
Journal:  Mod Pathol       Date:  1994-04       Impact factor: 7.842

View more
  18 in total

Review 1.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 2.  Diagnostic role of galectin-3 in follicular thyroid tumors.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-03-04       Impact factor: 4.064

Review 3.  Update in thyroid fine needle aspiration.

Authors:  William C Faquin; Massimo Bongiovanni; Peter M Sadow
Journal:  Endocr Pathol       Date:  2011-12       Impact factor: 3.943

Review 4.  How to define follicular thyroid carcinoma?

Authors:  Kurt Werner Schmid; Nadir Rashad Farid
Journal:  Virchows Arch       Date:  2006-02-28       Impact factor: 4.064

5.  Strong expression of HBME-1 associates with high-risk clinicopathological factors of papillary thyroid carcinoma.

Authors:  Tijana M Isic Dencic; Svetlana B Savin; Sonja A Selemetjev; Svetlana D Paskas; Vladan R Zivaljevic; Vesna D Bozic; Dubravka S Cvejic
Journal:  Pathol Oncol Res       Date:  2015-01-11       Impact factor: 3.201

Review 6.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

7.  ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.

Authors:  Electron Kebebew; Miao Peng; Emily Reiff; Quan-Yang Duh; Orlo H Clark; Alex McMillan
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

8.  Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Roberta DePompa; Enrico Saggiorato; Armando Bartolazzi; Fabio Orlandi; Mauro Papotti
Journal:  Virchows Arch       Date:  2004-07-14       Impact factor: 4.064

9.  Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms.

Authors:  Electron Kebebew; Miao Peng; Emily Reiff; Quan-Yang Duh; Orlo H Clark; Alex McMillan
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

10.  Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.

Authors:  E Saggiorato; S Aversa; D Deandreis; F Arecco; A Mussa; B Puligheddu; S Cappia; S Conticello; M Papotti; F Orlandi
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.